Carmen Griñán‐Lisón
- Cancer Research top 5%
- MicroRNA in disease regulation 10
- Oncology top 10%
- Cancer Cells and Metastasis 14
- Pancreatic and Hepatic Oncology Research 4
- Drug Discovery top 10%
-
- Epigenetics and DNA Methylation 4
- RNA Interference and Gene Delivery 3
- CRISPR and Genetic Engineering 3
-
- Virus-based gene therapy research 3
-
- Immunotherapy and Immune Responses 3
- Co-authors
- Juan Antonio MarchalGema JiménezMarı́a Isabel NúñezMaría Ángel GarcíaHouría BoulaizMacarena PeránCynthia Morata‐TarifaElena López‐Ruiz
- Journals
- Oncogene (1 paper)Scientific Reports (3 papers)International Journal of Molecular Sciences (3 papers)
- Partner nations
- SpainItalyUnited States
In The Last Decade
Carmen Griñán‐Lisón
35 papers receiving 962 citations
Peers
Comparison fields: 5 of 106
- Cancer Research 318
- Oncology 342
- Drug Discovery 2
- Molecular Biology 512
- Biomaterials 88
Countries citing papers authored by Carmen Griñán‐Lisón
This map shows the geographic impact of Carmen Griñán‐Lisón's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carmen Griñán‐Lisón with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carmen Griñán‐Lisón more than expected).
Fields of papers citing papers by Carmen Griñán‐Lisón
This network shows the impact of papers produced by Carmen Griñán‐Lisón. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carmen Griñán‐Lisón. The network helps show where Carmen Griñán‐Lisón may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Carmen Griñán‐Lisón, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2025 | 0 | |
| 3 | 2025 | 2 | |
| 4 | 2024 | 3 | |
| 5 | 2024 | 2 | |
| 6 | 2024 | 7 | |
| 7 | 2024 | 2 | |
| 8 | 2023 | 7 | |
| 9 | 2023 | 5 | |
| 10 | 2022 | 18 | |
| 11 | 2021 | 29 | |
| 12 | 2021 | 56 | |
| 13 | 2021 | 48 | |
| 14 | 2020 | 20 | |
| 15 | 2020 | 162 | |
| 16 | 2019 | 13 | |
| 17 | 2019 | 9 | |
| 18 | 2017 | 12 | |
| 19 | 2017 | 12 | |
| 20 | 2016 | 95 |
About Carmen Griñán‐Lisón
Carmen Griñán‐Lisón is a scholar working on Cancer Research, Oncology and Molecular Biology, having authored 39 papers that have together received 969 indexed citations. Recurring topics across this work include Cancer Cells and Metastasis (14 papers), MicroRNA in disease regulation (10 papers), Pancreatic and Hepatic Oncology Research (4 papers), Epigenetics and DNA Methylation (4 papers), Virus-based gene therapy research (3 papers), RNA Interference and Gene Delivery (3 papers), CRISPR and Genetic Engineering (3 papers) and Immunotherapy and Immune Responses (3 papers). The work is most often cited by research in Cancer Research (318 citations), Oncology (342 citations) and Drug Discovery (2 citations). Carmen Griñán‐Lisón has collaborated with scholars based in Spain, Italy and United States. Frequent co-authors include Juan Antonio Marchal, Gema Jiménez, Marı́a Isabel Núñez, María Ángel García, Houría Boulaiz, Macarena Perán, Cynthia Morata‐Tarifa, Elena López‐Ruiz, Esmeralda Carrillo and Saúl A. Navarro-Marchal. Their work appears in journals such as Oncogene, Scientific Reports and International Journal of Molecular Sciences.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.